SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to the FDA accepting its supplemental BLA for the label expansion of Anktiva, setting a PDUFA date for early January 2027. Community discussion is heavily focused on the stock's significant short interest and the potential for a squeeze, with many longs pointing to the recent NCCN guideline updates and comparative clinical data as drivers for long-term growth despite near-term volatility.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether the stock has hit a bottom, with many pointing to recent insider buying and high-profile endorsements as potential catalysts for a turnaround. However, community sentiment remains deeply divided, as traders express significant frustration over persistent price weakness and the stock's failure to maintain momentum.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing significant volatility and a sharp pullback as traders react to a broader market sell-off, surging bond yields, and persistent uncertainty surrounding global energy prices. While some community members are treating the drop as a long-term accumulation opportunity, many others are actively debating whether this signals a major trend reversal or if price manipulation is being used to clear out retail call positions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently the focal point of the market as investors anxiously await earnings results that many view as a critical bellwether for the entire AI infrastructure sector. The community is heavily divided, with intense debate over whether the stock will repeat its historical pattern of post-earnings selling or if it will catalyze a significant, sustained rally that boosts broader tech valuations.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate the final REGAL trial unblinding, with bullish sentiment fueled by management's recent commentary regarding extended GPS survival outcomes and its potential to outcompete existing maintenance therapies. The community is actively discussing an imminent short squeeze driven by heavy short interest and institutional accumulation, while emphasizing the importance of holding shares and avoiding stop-loss orders in anticipation of a transformative data readout.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending due to a recently announced $4.2 billion acquisition by Hapag-Lloyd at $35 per share, sparking intense community debate over the deal's viability, the potential for a bidding war, and the impact of the Israeli government's 'golden share' on final approval. Investors are actively discussing the arbitrage opportunity presented by the price gap between the current market value and the buyout offer, while weighing risks related to ongoing labor strikes and geopolitical tensions in the Middle East.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is gaining momentum as investors react positively to the company's upbeat fiscal forecasts and a strategic $2 billion turnaround plan aimed at reinvigorating growth through store expansions and enhanced digital capabilities. The retail community is actively debating whether this performance signals a definitive bottom for the stock or if persistent inflationary pressures on consumer spending will ultimately hinder the company's long-term recovery.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is trending sharply higher after reporting strong quarterly earnings and raising its full-year guidance, which has fueled intense community discussion regarding its rapid expansion and market share growth. While bulls are highlighting the restaurant chain's robust same-store sales and healthy balance sheet as indicators for long-term potential, skeptics are actively debating whether the stock's premium valuation is sustainable in the current macro environment.

Analog Devices, Inc. is a semiconductor company, which engages in the combination of analog, digital, and software technologies into engineering solutions. Its products include analog and mixed signals, power management and reference, amplifiers radio frequency, and reference, sensors and actuators, and digital signal processing and system. The company was founded by Raymond P. Stata and Matthew Lorber in 1965 and is headquartered in Wilmington, MA.

Analog Devices Inc.

Analog Devices is trending following a strong quarterly performance where the company delivered a double beat on earnings and revenue, signaling a robust recovery in the analog semiconductor sector. Investors are particularly focused on the company's strategic acquisition of Empower Semiconductor to bolster its AI power delivery capabilities and its positive growth outlook across industrial and communications markets.

Keysight Technologies, Inc. engages in the provision of electronic design and test solutions that are used in the design, development, manufacture, installation, deployment, validation, optimization, and secure operation of electronics systems to communications, networking, and electronics industries. It operates through the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The CSG segment serves customers spanning the global commercial communications and aerospace, defense, and government end markets. The EISG segment offers test and measurement solutions across electronic industrial end markets, focusing on applications in the automotive, and energy industry and measurement solutions for semiconductor design and manufacturing, consumer electronics, education, and general electronics manufacturing. The company was founded by William R. Hewlett and David Packard in 1937 and is headquartered in Santa Rosa, CA.

Keysight Technologies Inc

Keysight Technologies is seeing heightened investor attention following a fiscal quarter earnings report that topped expectations, with the community actively debating whether the company's strong order momentum and AI infrastructure exposure represent a sustained uptrend or a cyclical cycle. While some traders are focused on short-term price action and potential gap fills, institutional sentiment remains supportive as multiple firms have raised their price targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen

Wall Street Zen raised Fulcrum Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday...

HC Wainwright Issues Optimistic Estimate for FULC Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a research...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has i...

Fulcrum Therapeutics (NASDAQ:FULC) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) posted its earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06...

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - Time to Sell?

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - Time to Sell...

Fulcrum Therapeutics Q1 Earnings Call Highlights

Fulcrum Therapeutics (NASDAQ:FULC) highlighted new clinical and corporate progress during its first-quarter 2026 financial results and business update call, with management emphasizing positive Phase...

Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript

Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.9% - Time to Sell?

Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.9% - Here's What Happened...

Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Grows By 41.1%

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling...

Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Fulcrum Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday...

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

FULC
Fulcrum Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest FULC News

FULCFulcrum Therapeutics Inc